Tubulis secures €344M in Series C funding to accelerate TUB-040 development, advance its pipeline and expand ADC-technology innovations.

The prediction market raised $1 billion in a new funding round and landed a market value almost double that of rival Polymarket. But legal challenges to its business persist.

Zai Lab, a biopharma company listed on Nasdaq and the Hong Kong exchange, has agreed to raise about $250 million in a private placement. It will sell 11,340,000 American Depositary Shares at $22.04 each, with each share representing ten ordinary shares. TCGX leads the round. Other investors include abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Sirenia Capital Management, Wellington Management, and Woodline Partners. Zai Lab will mainly use the proceeds to support global development of zocilurtatug pelitecan, its DLL3-targeting antibody-drug conjugate. The deal is expected to close on or about October 27, 2026.